Alector, Inc.
ALEC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALEC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALEC
Alector, Inc. (ALEC) is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative diseases, with a lead program in frontotemporal dementia (FTD-GRN) partnered with GSK and a proprietary blood-brain barrier delivery platform.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 10 clinical trials for Alector, Inc..
Similar companies
Alector, Inc. (ALEC) is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative diseases, with a lead program in frontotemporal dementia (FTD-GRN) partnered with GSK and a proprietary blood-brain barrier delivery platform.
- Lead candidate latozinemab (partnered with GSK) received FDA Breakthrough Therapy Designation in February 2024 for FTD-GRN; topline data from the pivotal INFRONT-3 Phase 3 trial expected by Q4 2025 [sec · filed 2025-04-24].
- As of June 30, 2026, the company reported cash & equivalents of $61.8M, total revenue of $3.3M, and a net loss of $23.0M [sec].
- Accumulated deficit reached $1,018.0 million as of mid-2026, reflecting substantial R&D and G&A costs [sec_mda · as of 2026-08-06].
- In March 2025, the company committed to a workforce reduction of approximately 13% to manage expenses [sec_mda · as of 2026-08-06].
- Alector's pipeline includes nivisnebart (formerly AL101/GSK4527226), a PGRN-elevating antibody in a Phase 2 study for early Alzheimer's disease [sec_mda · as of 2026-02-25].
What works
- Latozinemab has FDA Breakthrough Therapy Designation, which may accelerate development and regulatory review for FTD-GRN [sec · filed 2025-04-24].
- The company's proprietary ABC technology for blood-brain barrier transport aims to improve CNS exposure of therapeutic modalities [sec_mda · as of 2026-02-25].
- Alector's partnership with GSK provides co-development resources and potential commercialization support for latozinemab [sec · filed 2025-04-24].
- The pipeline targets genetically validated mechanisms in neurodegeneration, which may increase the probability of clinical success [sec · filed 2025-04-24].
What to weigh
- The company has an accumulated deficit of $1,018.0 million as of mid-2026, with no approved products and ongoing operating losses [sec_mda · as of 2026-08-06].
- Cash & equivalents of $61.8M as of June 30, 2026, may be insufficient to fund all planned programs without additional financing [sec].
- Alector implemented a 13% workforce reduction in March 2025, indicating cost pressures and potential delays in pipeline execution [sec_mda · as of 2026-08-06].
- The company expects expenses to increase substantially as it advances clinical trials and regulatory activities, which could further strain financial resources [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
FDA granted Breakthrough Therapy Designation to latozinemab in February 2024.
“In February 2024, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy Designation ("BTD") to latozinemab”
SEC filings · April 24, 2025
Topline data from the INFRONT-3 Phase 3 trial expected by Q4 2025.
“we expect topline data by the fourth quarter of 2025”
SEC filings · April 24, 2025
Accumulated deficit of $1,018.0 million as of mid-2026.
“2026, we had an accumulated deficit of $1,018.0 million”
SEC MD&A · August 6, 2026
Workforce reduction of approximately 13% in March 2025.
“On March 7, 2025, we committed to a plan to reduce our workforce by approximately 13%”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Latozinemab Phase 3 topline data expected Q4 2025; negative results would severely impact pipeline value [sec · filed 2025-04-24].
- Cash runway uncertainty — Cash of $61.8M as of June 30, 2026, may not sustain operations beyond near term without new financing [sec].
- Regulatory and development delays — Expenses expected to increase substantially; workforce reduction may slow program execution [sec_mda · as of 2026-08-06].
- Dependence on GSK partnership — Latozinemab development relies on GSK collaboration; changes in partnership could disrupt progress [sec · filed 2025-04-24].
What to watch
- Topline data from the INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN, expected by Q4 2025 [sec · filed 2025-04-24].
- Cash position and any new financing or partnership deals to extend runway beyond current $61.8M [sec].
- Progress of nivisnebart (AL101) in the Phase 2 Alzheimer's study and any biomarker readouts [sec_mda · as of 2026-02-25].
- Updates on the workforce reduction and its impact on R&D timelines and operational costs [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Alector, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alector, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
15.0 months
OCF -$34M · Net income -$23M
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 7 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$147.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,741,245 | $16.6M |
| vanguard capital management llc | 7,357,444 | $15.8M |
| d. e. shaw & co., inc. | 3,332,835 | $7.2M |
| 683 capital management, llc | 3,200,000 | $6.9M |
| balyasny asset management l.p. | 2,935,253 | $6.3M |
| vanguard portfolio management llc | 2,583,542 | $5.6M |
| geode capital management, llc | 2,286,218 | $4.9M |
| jacobs levy equity management, inc | 2,154,361 | $4.6M |
| spruce street capital lp | 2,101,068 | $4.5M |
| ikarian capital, llc | 2,082,606 | $4.5M |
Showing top 10 of 133 institutional holders of Alector, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 7.0%
- Days to cover
- 8.2
- Shares short
- 6,284,391
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALEC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alector, Inc.?
Alector, Inc. (ALEC) is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative diseases, with a lead program in frontotemporal dementia (FTD-GRN) partnered with GSK and a proprietary blood-brain barrier delivery platform.
What is Alector, Inc.'s lead drug candidate?
Alector, Inc.'s most advanced tracked candidate is Latozinemab (AL001) (Phase 3) for Frontotemporal Dementia; Amyotrophic Lateral Sclerosis.
Who is the CEO of Alector, Inc.?
Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector, Inc. (ALEC).
Where is Alector, Inc. headquartered?
Alector, Inc. (ALEC) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Alector, Inc. focus on?
Alector, Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.